SummitTX Capital L.P. Has $756,000 Position in Perrigo Company plc $PRGO

Posted by George Bondi on Jul 31st, 2026

SummitTX Capital L.P. lessened its stake in Perrigo Company plc (NYSE:PRGO – Free Report) by 48.0% during the first quarter, HoldingsChannel reports. The institutional investor owned 70,375 shares of the company’s stock after selling 64,883 shares during the period. SummitTX Capital L.P.’s holdings in Perrigo were worth $756,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Amundi raised its position in shares of Perrigo by 11.7% during the first quarter. Amundi now owns 5,292 shares of the company’s stock worth $148,000 after acquiring an additional 556 shares during the last quarter. Goldman Sachs Group Inc. boosted its holdings in Perrigo by 126.6% in the first quarter. Goldman Sachs Group Inc. now owns 1,159,768 shares of the company’s stock valued at $32,520,000 after acquiring an additional 647,982 shares during the last quarter. United Services Automobile Association acquired a new stake in Perrigo during the 1st quarter valued at approximately $250,000. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its position in Perrigo by 6.7% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 513,112 shares of the company’s stock valued at $14,388,000 after purchasing an additional 32,151 shares during the period. Finally, Geneos Wealth Management Inc. raised its holdings in Perrigo by 439.1% during the 1st quarter. Geneos Wealth Management Inc. now owns 965 shares of the company’s stock worth $27,000 after purchasing an additional 786 shares during the last quarter. Institutional investors and hedge funds own 95.91% of the company’s stock.

Perrigo Stock Down 0.6%

Shares of NYSE:PRGO opened at $10.36 on Friday. Perrigo Company plc has a 1 year low of $9.23 and a 1 year high of $27.33. The company has a debt-to-equity ratio of 1.45, a current ratio of 2.72 and a quick ratio of 1.59. The business’s 50-day moving average is $10.55 and its 200-day moving average is $11.65. The company has a market capitalization of $1.43 billion, a price-to-earnings ratio of -0.79, a P/E/G ratio of 1.24 and a beta of 0.51.

Perrigo (NYSE:PRGO – Get Free Report) last released its earnings results on Wednesday, May 6th. The company reported $0.43 EPS for the quarter, topping the consensus estimate of $0.39 by $0.04. The business had revenue of $841.80 million during the quarter, compared to analysts’ expectations of $1.04 billion. Perrigo had a positive return on equity of 9.96% and a negative net margin of 43.50%.The firm’s revenue was down 7.2% on a year-over-year basis. During the same quarter last year, the firm posted $0.60 earnings per share. Perrigo has set its FY 2026 guidance at 2.250-2.550 EPS. Equities research analysts predict that Perrigo Company plc will post 2.11 earnings per share for the current year.

Perrigo Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 15th. Stockholders of record on Friday, August 28th will be given a dividend of $0.29 per share. The ex-dividend date of this dividend is Friday, August 28th. This represents a $1.16 annualized dividend and a dividend yield of 11.2%. Perrigo’s dividend payout ratio (DPR) is -8.85%.

Analyst Upgrades and Downgrades

A number of research analysts have recently issued reports on the stock. Zacks Research upgraded shares of Perrigo from a “strong sell” rating to a “hold” rating in a research report on Monday, April 27th. Weiss Ratings upgraded shares of Perrigo from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Tuesday, July 21st. One investment analyst has rated the stock with a Buy rating, four have assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus price target of $19.33.

Get Our Latest Research Report on PRGO

About Perrigo

(Free Report)

Perrigo Company plc is a global healthcare supplier specializing in over-the-counter (OTC) and self-care products, as well as generic prescription pharmaceuticals and active pharmaceutical ingredients. The company develops, manufactures and distributes a broad array of consumer health products, including analgesics, vitamins and supplements, digestive health remedies, topical treatments, and infant formulas. Perrigo’s focus on private-label solutions has made it a leading partner for retailers and pharmacy chains seeking high-quality, value-oriented alternatives to branded medications and health supplements.

Organized across three principal business segments—Consumer Healthcare, Prescription Pharmaceuticals and Active Pharmaceutical Ingredients—Perrigo’s operations span research and development, manufacturing, quality assurance and global distribution.